Advanced search
Publication Cover
Expert Review of Vaccines Volume 11, 2012 - Issue 3
Submit an article Journal homepage
138
Views
40
CrossRef citations to date
0
Altmetric
Special Report

Issues and challenges in the development of pneumococcal protein vaccines

Amy Sarah Ginsburg PATH, Seattle, WA, USA. [email protected]; PATH, Seattle, WA, USA
,
Moon H Nahm University of Alabama at Birmingham, Birmingham, AL, USA; University of Alabama at Birmingham, Birmingham, AL, USA
,
Farukh M Khambaty National Institutes of Health, Bethesda, MD, USA; National Institutes of Health, Bethesda, MD, USA
&
Mark R Alderson PATH, Seattle, WA, USA; PATH, Seattle, WA, USA
Pages 279-285 | Published online: 09 Jan 2014

References

  • O'Brien KL, Wolfson LJ, Watt JP et al. Burden of disease caused by Streptococcus pneumoniae in children younger than 5 years: global estimates. Lancet 374(9693), 893–902 (2009).
  • Lynch JP III, Zhanel GG. Streptococcus pneumoniae: epidemiology and risk factors, evolution of antimicrobial resistance, and impact of vaccines. Curr. Opin. Pulm. Med. 16(3), 217–225 (2010).
  • Cole R. Treatment of pneumonia by means of specific serums. JAMA 61(9), 663–666 (1913).
  • Whitney CG, Farley MM, Hadler J et al. Decline in invasive pneumococcal disease after the introduction of protein-polysaccharide conjugate vaccine. N. Engl. J. Med. 348(18), 1737–1746 (2003).
  • Hausdorff WP, Dagan R, Beckers F, Schuerman L. Estimating the direct impact of new conjugate vaccines against invasive pneumococcal disease. Vaccine 27(52), 7257–7269 (2009).
  • Centers for Disease Control and Prevention (CDC). Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly Rep. 59(9), 258–261 (2010).
  • Hennessy TW, Bulkow LR, Hammitt LL et al. Invasive pneumococcal disease caused by nonvaccine serotypes among Alaska native children with high levels of 7-valent pneumococcal conjugate vaccine coverage. JAMA 297(16), 1784–1792 (2007).
  • Lu YJ, Gross J, Bogaert D et al. Interleukin-17A mediates acquired immunity to pneumococcal colonization. PLoS Pathog. 4(9), e1000159 (2008).
  • Prymula R, Peeters P, Chrobok V et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study. Lancet 367(9512), 740–748 (2006).
  • Prymula R, Schuerman L. 10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix. Expert Rev. Vaccines 8(11), 1479–1500 (2009).
  • Briles DE, Hollingshead SK, King J et al. Immunization of humans with recombinant pneumococcal surface protein A (rPspA) elicits antibodies that passively protect mice from fatal infection with Streptococcus pneumoniae bearing heterologous PspA. J. Infect. Dis. 182(6), 1694–1701 (2000).
  • Hausdorff WP, Hoet B, Schuerman L. Do pneumococcal conjugate vaccines provide any cross-protection against serotype 19A? BMC Pediatr. 10, 4 (2010).
  • Opalka D, Lachman CE, MacMullen SA et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin. Diagn. Lab. Immunol. 10(1), 108–115 (2003).
  • Huang SS, Platt R, Rifas-Shiman SL, Pelton SI, Goldmann D, Finkelstein JA. Post-PCV7 changes in colonizing pneumococcal serotypes in 16 Massachusetts communities, 2001 and 2004. Pediatrics 116(3), e408–e413 (2005).
  • Van Gils EJ, Veenhoven RH, Hak E et al. Effect of reduced-dose schedules with 7-valent pneumococcal conjugate vaccine on nasopharyngeal pneumococcal carriage in children: a randomized controlled trial. JAMA 302(2), 159–167 (2009).
  • Frazao N, Sa-Leao R, de Lencastre H. Impact of a single dose of the 7-valent pneumococcal conjugate vaccine on colonization. Vaccine 28(19), 3445–3452 (2010).

Website

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.